FMC Corporation

Fundamentals6.0
Price Action6.0
News Sentiment6.0
AI Rating
5.0

Key Drivers

  • High gross margins
  • Deep operating losses
  • Elevated leverage

AI
AI Summary

5.0

FMC has shifted from a product-led growth story to a de‑leveraging/restructuring trade—management's $1B debt-reduction target against ~\$4B net debt and negative-ish near‑term FCF means upside now depends on timely asset sales/licensing and execution (not organic margin expansion). Actionable watch‑points: confirm announced asset-sale proceeds/timing, Latin America cash-recovery and no further large impairments, and debt reduction progress before re-rating.

Deleveraging
ExecutionRisk
Leverage‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • High gross margins
  • Deep operating losses
  • Elevated leverage

FMC shows strong product-level gross margins but is undermined by persistent operating losses, high leverage, and volatile cash flow that create substantial execution and capital-risk despite low headline valuation multiples.

execution_risk
undervalued

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Short-term downtrend
  • Below moving average
  • Volatile swings

Over the last month FMC dropped about 10.5% to $13.09 and trading below the last-month SMA (~$14.13) signals a short-term downtrend that needs a reclaim above $14.13 and a break of $14.74–$14.97 to reverse, while failure to hold $13.00–$13.75 risks further losses.

bearish
monitor
Support Level: $13.00–$13.75
Resistance Level: $14.74–$14.97

Intra-period swings of ~12–13% from local high to recent low

Sentiment & News

6.0

Key News Insights:

  • Dual‑mode herbicide
  • Legal investigations
  • Dividend/impairment

FMC shows product and governance progress (notably a dual‑mode herbicide and board/dividend actions) but faces analyst downgrades, legal probes, impaired assets and strategic pressure after rebuffing a $30/share bid.

investor_risk
product_progress

Elevated legal and operational scrutiny plus muted analyst sentiment likely keeps downside pressure on the stock until clear execution or strategic actions reduce leverage and litigation risk